BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
32981551
Number of visits today
6292
Number of downloads
16155799
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Sabnis RW. Novel Substituted Tetrazoles as ACSS2 Inhibitors for Treating Cancer. ACS Med Chem Lett 2021;12:1894-5. [PMID: 34917250 DOI: 10.1021/acsmedchemlett.1c00621] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hao Y, Yi Q, Xiaowu X, Weibo C, Guangchen Z, Xuemin C. Acetyl-CoA: An interplay between metabolism and epigenetics in cancer. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.1044585] [Reference Citation Analysis]
2 Cui M, Yi X, Cao Z, Zhu D, Wu J, Raghavamenon AC. Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4257359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kou Y, Geng F, Guo D. Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage. Biomedicines 2022;10:1943. [DOI: 10.3390/biomedicines10081943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ling R, Chen G, Tang X, Liu N, Zhou Y, Chen D. Acetyl-CoA synthetase 2(ACSS2): a review with a focus on metabolism and tumor development. Discov Oncol 2022;13:58. [PMID: 35798917 DOI: 10.1007/s12672-022-00521-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu M, Liu N, Wang J, Fu S, Wang X, Chen D. Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism. Cancers (Basel) 2022;14:2896. [PMID: 35740562 DOI: 10.3390/cancers14122896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345